Astrazeneca (AZN)

 

Latest News

Broker Forecast - HSBC issues a broker note on AstraZeneca PLC

HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 4380p (f...

AZ Fasenra gets FDA approval for severe asthma

AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and D...

AZ Fasenra receives FDA approval for severe asthma

RNS Number: 5114W AstraZeneca PLC 14 November 2017 This announcement contains inside information 14 November 2017 22:45 GMT FASENRA (BENRALIZUMAB) RECEIVES US FDA APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA Fasenra distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maint...

AstraZeneca receives positive EU CHMP opinion for asthma treatment

AstraZeneca has confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicin...

All News

DateHeadlineSource
16-11-17Broker Forecast - HSBC issues a broker note on AstraZeneca PLCStockMarketWire
15-11-17 AZ Fasenra gets FDA approval for severe asthmaStockMarketWire
15-11-17AZ Fasenra receives FDA approval for severe asthmaRNS
10-11-17AstraZeneca receives positive EU CHMP opinion for asthma treatmentStockMarketWire
10-11-17BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMARNS
09-11-17FTSE 100 dips after weak Wall Street tradingStockMarketWire
09-11-17AstraZeneca operating profits rise StockMarketWire
09-11-17AZN: Year-To-Date and Q3 2017 Results AnnouncementRNS
08-11-17How I am preparing for a stockmarket correctionInteractive Investor
03-11-17Have Neil Woodford and these three other star managers lost their Midas touch?Interactive Investor
01-11-17Total Voting RightsRNS
01-11-17Broker Forecast - Kepler Cheuvreux issues a broker note on AstraZeneca PLCStockMarketWire
01-11-17AZ's tralokinumab disappoints in two trials StockMarketWire
01-11-17US FDA approves AstraZeneca's Calquence for MCLStockMarketWire
01-11-17AZ and Aspen complete anaesthetics deal StockMarketWire
01-11-17ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEALRNS
01-11-17AstraZeneca tralokinumab update in severe asthmaRNS
31-10-17US FDA approves AstraZeneca's Calquence for MCLRNS
25-10-17How come GlaxoSmithKline just plunged 6%?Interactive Investor
23-10-17AZ and MSD rapidly advance Lynparza in JapanStockMarketWire
23-10-17AZ diabetes medicine gets FDA approval StockMarketWire
23-10-17AZ and MSD rapidly advance Lynparza in JapanRNS
23-10-17US FDA approves Bydureon BCise for type-2 diabetesRNS
18-10-17FDA priority review for Lynparza in breast cancer, says AZStockMarketWire
18-10-17FDA Priority Review for Lynparza in breast cancerRNS
17-10-17AZ lung cancer drug granted priority review statusStockMarketWire
17-10-17FDA accepts sBLA file for Imfinzi; priority reviewRNS
16-10-17Broker Forecast - Credit Suisse issues a broker note on AstraZeneca PLCStockMarketWire
16-10-17Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLCStockMarketWire
11-10-17A debt warning and short selling Interactive Investor
09-10-17Broker Forecast - HSBC issues a broker note on AstraZeneca PLCStockMarketWire
09-10-17AZN cancer drug granted breakthrough therapy designation StockMarketWire
09-10-17FDA grants Tagrisso BTD for 1st-line EGFR nsclcRNS
02-10-17Total Voting RightsRNS
26-09-17Director/PDMR ShareholdingRNS
18-09-17Neil Woodford's trades in August 2017Interactive Investor
14-09-17Be patient with Neil Woodford Interactive Investor
14-09-17Aspen acquires remaining rights to AZ anaestheticsStockMarketWire
14-09-17Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLCStockMarketWire
14-09-17Aspen acquires remaining rights to AZ anaestheticsRNS

RSS feeds

  • Editorial news feed for LSE:AZN Editorial
  • Regulatory news feed for LSE:AZN Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account